Citation: Jun Chen, Jing Yang, Fangfang Chang, Yabin Hu, Qian Wu, Shishan Teng, Yongchen Liu, Jian Zhang, Rongzhang He, Bo Liu, Xingyu Zheng, Ze Liu, Yanxi Peng, Zhenhua Xie, Yuanfang Zhang, Rui Lu, Dong Pan, You Wang, Liting Peng, Wenpei Liu, Yi-Ping Li, Xiaowang Qu. Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients .VIROLOGICA SINICA, 2023, 38(2) : 313-316.  http://dx.doi.org/10.1016/j.virs.2023.01.005

Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients

  • Highlights
    1. SARS-CoV-2 variants, particularly BF.7 and BQ.1, escaped most neutralizing antibodies isolated from the recovered COVID-19 individuals and vaccine recipients.
    2. Five potent neutralizing antibodies were identified that showed a broad neutralizing profile to Omicron subvariants and other VOCs.
    3. These broad neutralizing antibodies targeted the receptor binding domain of the spike protein, competing with ACE2 for binding.

  • 加载中
    1. Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. 2022. Antibody evasion of sars-cov-2 omicron ba.1, ba.1.1, ba.2, and ba.3 sub-lineages. Cell Host Microbe, 30:1077-1083 e1074.

    2. Callaway E. 2021. Heavily mutated omicron variant puts scientists on alert. Nature, 600:21.

    3. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. 2022. Ba.2.12.1, ba.4 and ba.5 escape antibodies elicited by omicron infection. Nature, 608:593-602.

    4. Desingu PA, Nagarajan K, Dhama K. 2022. Emergence of omicron third lineage ba.3 and its importance. J Med Virol, 94:1808-1810.

    5. Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Galao RP, Dupont L, Lista MJ, Jimenez-Guardeno JM, Laing AG, Wu Y, Joseph M, Muir L, van Gils MJ, Ng WM, Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE, Hayday AC, Neil SJD, Malim MH, Doores KJ. 2021. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on sars-cov-2 spike is impacted by the b.1.1.7 variant. Immunity, 54:1276-1289 e1276.

    6. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Sander LE, Kurth F, Klein F. 2022a. Neutralisation sensitivity of the sars-cov-2 omicron ba.2.75 sublineage. Lancet Infect Dis, 22:1422-1423.

    7. Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Munn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. 2022b. Sars-cov-2 omicron sublineages exhibit distinct antibody escape patterns. Cell Host Microbe, 30:1231-1241.

    8. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K, Barouch DH. 2022. Neutralization escape by sars-cov-2 omicron subvariants ba.2.12.1, ba.4, and ba.5. N Engl J Med, 387:86-88.

    9. Hentzien M, Autran B, Piroth L, Yazdanpanah Y, Calmy A. 2022. A monoclonal antibody stands out against omicron subvariants:A call to action for a wider access to bebtelovimab. Lancet Infect Dis, 22:1278.

    10. Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, Cooper D, Muik A, Jansen KU, Xie X, Swanson KA, Shi PY. 2022. Neutralization of omicron ba.1, ba.2, and ba.3 sars-cov-2 by 3 doses of bnt162b2 vaccine. Nat Commun, 13:3602.

    11. Qu P, Evans JP, Faraone J, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Lozanski G, Panchal A, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. 2022. Distinct neutralizing antibody escape of sars-cov-2 omicron subvariants bq.1, bq.1.1, ba.4.6, bf.7 and ba.2.75.2. bioRxiv.

    12. Tan CW, Lim BL, Young BE, Yeoh AY, Yung CF, Yap WC, Althaus T, Chia WN, Zhu F, Lye DC, Wang LF. 2022. Comparative neutralisation profile of sars-cov-2 omicron subvariants ba.2.75 and ba.5. Lancet Microbe, 3:e898.

    13. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, Msomi N, consortium N-S, Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-Lawrence P, Stevens W, Dor G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Chiloane G, McIntyre C, O'Toole A, Ruis C, Peacock TP, Roemer C, Kosakovsky Pond SL, Williamson C, Pybus OG, Bhiman JN, Glass A, Martin DP, Jackson B, Rambaut A, Laguda-Akingba O, Gaseitsiwe S, von Gottberg A, de Oliveira T. 2022. Emergence of sars-cov-2 omicron lineages ba.4 and ba.5 in south africa. Nat Med, 28:1785-1790.

    14. Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, Sato K, Genotype to Phenotype Japan C. 2022a. Neutralisation sensitivity of sars-cov-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis, 22:942-943.

    15. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G, Genotype to Phenotype Japan C, Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. 2022b. Virological characteristics of the sars-cov-2 omicron ba.2 spike. Cell, 185:2103-2115 e2119.

  • 加载中

Article Metrics

Article views(1864) PDF downloads(15) Cited by()

Related
Proportional views

    Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients

      Corresponding author: Wenpei Liu, wenpeiliu_2008@foxmail.com
      Corresponding author: Yi-Ping Li, lyiping@mail.sysu.edu.cn
      Corresponding author: Xiaowang Qu, quxiaowang@163.com
    • a. School of Public Health, Southern Medical University, Guangzhou, 510515, China;
    • b. School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China;
    • c. Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, 423000, China;
    • d. Institute of Human Virology, Department of Pathogen Biology and Biosecurity, and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China;
    • e. School of Nursing, Xiangnan University, Chenzhou, 423000, China;
    • f. College of Basic Medicine, Xiangnan University, Chenzhou, 423000, China;
    • g. College of Pharmacy, Xiangnan University, Chenzhou, 423000, China;
    • h. School of Public Health, Hengyang Medical School, University of South China, Hengyang, 421001, China;
    • i. Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China

    Abstract: Highlights
    1. SARS-CoV-2 variants, particularly BF.7 and BQ.1, escaped most neutralizing antibodies isolated from the recovered COVID-19 individuals and vaccine recipients.
    2. Five potent neutralizing antibodies were identified that showed a broad neutralizing profile to Omicron subvariants and other VOCs.
    3. These broad neutralizing antibodies targeted the receptor binding domain of the spike protein, competing with ACE2 for binding.

    Reference (15) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return